Diabetes

Changes in Risk Indicators of MetS Severity Tied to T2DM Risk

Changes in Risk Indicators of MetS Severity Tied to T2DM Risk

For patients with prediabetes, changes in risk indicators during intervention tied to T2DM, CVD risk

AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM

AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM

Treatment resulted in lower HF hospitalization rate in patients with, without atherosclerosis.

Insulins

Insulin products chart with pharmacokinetic properties.

Bardoxolone Methyl Leads to Weight Loss in T2D With Concurrent Chronic Kidney Disease

Bardoxolone Methyl Leads to Weight Loss in T2D With Concurrent Chronic Kidney Disease

Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.

Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk

Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk

Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients

TRT May Reduce Mortality Without Improving CV Health in Diabetes

TRT May Reduce Mortality Without Improving CV Health in Diabetes

By

In a study, reduced mortality was found among TRT users with type 2 diabetes after adjustment for cardiovascular risk factors.

Canagliflozin Approved to Reduce Risk of Major Adverse Cardiovascular Events

Canagliflozin Approved to Reduce Risk of Major Adverse Cardiovascular Events

The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.

Canagliflozin Ups Survival in Type 2 Diabetes With Macroalbuminuria

Canagliflozin Ups Survival in Type 2 Diabetes With Macroalbuminuria

By

Canagliflozin vs placebo is associated with increased survival and renal outcomes in patients with type 2 diabetes and macroalbuminuria.

Glucose Dysregulation Seen Years Before Diabetes Diagnosis

Glucose Dysregulation Seen Years Before Diabetes Diagnosis

Fasting plasma glucose, BMI elevated 10 years before diagnosis of prediabetes, diabetes.

ADA, EASD Issue New Recommendations for T2DM

ADA, EASD Issue New Recommendations for T2DM

Additional focus on lifestyle management, self-management education and support emphasized

Intensive BP Therapy in Diabetes May Lower Risk for CV Events

Intensive BP Therapy in Diabetes May Lower Risk for CV Events

Findings based on data reweighted to reflect the adult population with diabetes in the US.

Lixisenatide Cuts Kidney Damage in T2DM and Coronary Syndrome

Lixisenatide Cuts Kidney Damage in T2DM and Coronary Syndrome

Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria.

Albiglutide Beats Placebo for Cardiovascular Events in T2DM

Albiglutide Beats Placebo for Cardiovascular Events in T2DM

Despite having been withdrawn, albiglutide is superior to placebo for reducing cardiovascular events

Diabetes Population Has Higher Incidences of Bladder, Kidney Cancer

Diabetes Population Has Higher Incidences of Bladder, Kidney Cancer

By

Finnish study of individuals with type 2 diabetes reveals a 17% and 42% higher incidence of bladder and kidney cancer, respectively, compared with the general population.

Diabetes Develops At a Higher Rate in the CKD Population

Diabetes Develops At a Higher Rate in the CKD Population

By

New study reveals a type 2 diabetes incidence rate of 17.81 cases per 1000 person-years, a rate much higher than in the general population.

Obesity Treatments

Treatment options for obesity including strength, form, and dosing details.

Diabetes Treatments

Antidiabetic agents for the treatment of diabetes including maintenance and max doses chart.

Plasma Copeptin More Accurate for Diabetes Insipidus Diagnosis

Plasma Copeptin More Accurate for Diabetes Insipidus Diagnosis

Measurement of plasma copeptin better than water-deprivation test in patients with hypotonic polyuria.

Sulfonylureas as 2nd-Line T2DM Therapy Tied to Higher Event Risk

Sulfonylureas as 2nd-Line T2DM Therapy Tied to Higher Event Risk

Associated with increased risk of myocardial infarction, all-cause mortality, severe hypoglycemia.

FDA Requires Safety Label Changes for Fluoroquinolones

FDA Requires Safety Label Changes for Fluoroquinolones

Changes will describe hypoglycemic coma and clarify and identify mental health side effects.

Working More Than 45 Hours Tied to Higher Diabetes Risk in Women

Working More Than 45 Hours Tied to Higher Diabetes Risk in Women

Increased risk seen for women but not men; slightly attenuated after adjustment for mediating factors.

FDA Approves Continuous Glucose Monitoring System

FDA Approves Continuous Glucose Monitoring System

Eversense CGM, which has fully implantable sensor to detect glucose, approved for adults with diabetes.

Metformin Added to Prostate Cancer ADT Ups Survival

Metformin Added to Prostate Cancer ADT Ups Survival

By

Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.

ADA: Closed-Loop Insulin Improves Glycemic Control

ADA: Closed-Loop Insulin Improves Glycemic Control

Better glycemic control than conventional subcutaneous insulin therapy in patients with T2DM.

Aspirin Use Doesn't Cut Cancer Incidence in Older T2DM Patients

Aspirin Use Doesn't Cut Cancer Incidence in Older T2DM Patients

In subgroup analyses, reduced incidence of cancer seen in participants aged younger than 65 years.

HbA1c Targets Should Be Personalized in Type 2 Diabetes

HbA1c Targets Should Be Personalized in Type 2 Diabetes

Target HbA1c 7 to 8 for most patients with T2DM; deintensification of tx with HbA1c 6.5

Elevated NT-proBNP Found to Up Cardiovascular Risk in T2DM

Elevated NT-proBNP Found to Up Cardiovascular Risk in T2DM

Independently linked to major cardiovascular events, especially heart failure hospitalizations.

Diabetes Meds Reconciliation May Reduce Risk of ER Visits

Diabetes Meds Reconciliation May Reduce Risk of ER Visits

Medication reconciliation linked to lower risk of combined ER visits, hospitalization over 6 months.

CKD Prevalence, Progression Rate High Among Elderly Diabetics

CKD Prevalence, Progression Rate High Among Elderly Diabetics

By

In a South Korean study, nearly 60% of elderly patients with type 2 diabetes had chronic kidney disease at baseline.

Cancer Development Linked to Increased Diabetes Risk

Cancer Development Linked to Increased Diabetes Risk

Increased risk of subsequent diabetes independent of traditional diabetes risk factors.

Sign Up for Free e-newsletters